These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 27069181

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
    Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Hasuike N, Inui T, Yamaguchi Y, Ono H.
    Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A combined therapy with docetaxel and nedaplatin for relapsed and metastatic esophageal carcinoma.
    Matsumoto H, Hirabayashi Y, Kubota H, Murakami H, Higashida M, Haruma K, Hiratsuka J, Nakamura M, Hirai T.
    Anticancer Res; 2012 May; 32(5):1827-31. PubMed ID: 22593469
    [Abstract] [Full Text] [Related]

  • 8. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
    Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z, Wang D.
    J Thorac Oncol; 2009 Aug; 4(8):1017-21. PubMed ID: 19542899
    [Abstract] [Full Text] [Related]

  • 9. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
    Akutsu Y, Shuto K, Kono T, Uesato M, Hoshino I, Shiratori T, Miyazawa Y, Isozaki Y, Akanuma N, Matsubara H.
    Hepatogastroenterology; 2012 Oct; 59(119):2095-8. PubMed ID: 22328303
    [Abstract] [Full Text] [Related]

  • 10. [An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance].
    Miura T, Hosojima Y, Nakamura J, Yamada S, Nakazawa Y, Ozeki Y, Miura T, Yanagi M, Yamazaki H, Takahashi T.
    Gan To Kagaku Ryoho; 2010 May; 37(5):883-5. PubMed ID: 20495320
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
    Miyazaki T, Ojima H, Fukuchi M, Sakai M, Sohda M, Tanaka N, Suzuki S, Ieta K, Saito K, Sano A, Yokobori T, Inose T, Nakajima M, Kato H, Kuwano H.
    Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
    [Abstract] [Full Text] [Related]

  • 14. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
    Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y, Ishioka C.
    Int J Clin Oncol; 2006 Dec; 11(6):454-60. PubMed ID: 17180514
    [Abstract] [Full Text] [Related]

  • 15. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N, West Japan Oncology Group.
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
    Tanaka Y, Yoshida K, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K.
    Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001
    [Abstract] [Full Text] [Related]

  • 17. [Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer].
    Kawada J, Iwase K, Deguchi K, Higashi S, Deguchi T, Matsuda C, Tamagawa H, Omori K, Nishikawa K, Nomura M, Takagi M, Fukui A, Tanaka Y.
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2095-7. PubMed ID: 23267988
    [Abstract] [Full Text] [Related]

  • 18. [Evaluation of combination chemotherapy with docetaxel and nedaplatin in patients with advanced or recurrent esophageal cancer].
    Funaki H, Miura S, Morioka E, Kaida D, Ohnishi T, Ohno Y, Tomita Y, Noguchi M, Fujita H, Kinami S, Nakano Y, Ueda N, Kosaka T.
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2384-6. PubMed ID: 25731531
    [Abstract] [Full Text] [Related]

  • 19. Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
    Miyazaki T, Sohda M, Tanaka N, Suzuki S, Ieta K, Sakai M, Sano A, Yokobori T, Inose T, Nakajima M, Fukuchi M, Ojima H, Kato H, Kuwano H.
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):853-7. PubMed ID: 23306309
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.